(308) Gestational Lipid Profile and Perinatal Morbidity: A Pilot Study

Thursday, January 30, 2025

10:30 AM – 12:30 PM

Submitting Author and Presenting Author(s)

Nicola F. Tavella, MPH (he/him/his)

Research Director
Icahn School of Medicine at Mount Sinai
New York, NY, United States

Coauthor(s)

Camila Cabrera, MD (she/her/hers)

Fellow
Icahn School of Medicine at Mount Sinai
New York, New York, United States
DM

Dayana Mirzaliev, MPH

Clinical Research Coordinator
Division of Maternal Fetal Medicine, Icahn School of Medicine at Mount Sinai West
New York, New York, United States
NP

Nicole Parkas, BS, RDMS

Medical Student
Division of Maternal-Fetal Medicine, Icahn School of Medicine at Mount Sinai
New York, New York, United States
CJ

Camila Johanek, MS

Icahn School of Medicine at Mount Sinai
New York, New York, United States
Laura Gilroy, MD (she/her/hers)

Assistant Professor
Division of Maternal Fetal Medicine, Icahn School of Medicine at Mount Sinai West
New York, New York, United States
Joanne L. Stone, MD, MS

professor
Division of Maternal Fetal Medicine, Icahn School of Medicine at Mount Sinai
New York, New York, United States
AB

Angela T. Bianco, MD

Professor
Icahn School of Medicine at Mount Sinai
New York, New York, United States
LV

Luciana A. Vieira, MD, MS

Stamford Hospital
Stamford, Connecticut, United States
Samsiya Ona, MD

Assistant Professor
Icahn School of Medicine at Mount Sinai
New York, New York, United States
NK

Nathan Kase, MD

Dean Emiritus
Icahn School of Medicine at Mount Sinai
New York, New York, United States

Objective: Lipid profile is a key metabolic predictor of risk related to perinatal morbidity. The study's objective was to determine if gestational maternal lipids were associated with composite perinatal morbidity.

Study Design: This was a prospective cohort study of pregnant patients at one urban hospital. We enrolled patients with singleton gestations from July 2022 to February 2024. We excluded patients with hyperlipidemia, hypercholesteremia, and pregestational diabetes. Patients provided two fasting blood samples, one in the second trimester and one in the third trimester. Lipid profile included high-density lipoprotein cholesterol (HDLc), low-density lipoprotein cholesterol (LDLc), very low-density lipoprotein cholesterol (vLDLc), total cholesterol (TC), triglycerides (TG), C-peptides, and free fatty acids (FFA). Composite perinatal morbidity included preterm birth (< 37 weeks’ gestation at delivery), gestational diabetes mellitus (GDM), hypertensive disorders of pregnancy (HDP), and a Fenton birth weight percentile < 10% or > 90%. Multivariable logistic regression models estimated odds ratios (aOR) of perinatal morbidity adjusted for maternal age and gestational weight gain.

Results: We included 100 patients in our analyses, and 35 (35.0%) experienced composite perinatal morbidity. Patients with an abnormal second-trimester TG (aOR 1.5) had a higher risk of perinatal morbidity. Patients with an abnormal third-trimester TG (aOR 2.3) had a higher risk of perinatal morbidity. Patients with a greater change in C-peptides (aOR 2.7), and FFA (aOR 36.2) had higher risk of perinatal morbidity. However, patients with a greater change in LDLc (aOR 0.97) had lower risk of perinatal morbidity.

Conclusion: Our results suggest significant associations between gestational lipid levels and composite perinatal morbidity. More detailed analyses among larger prospective cohorts are needed to further investigate these associations and determine the importance of gestational lipids in peripartum risk profiles.